Nexgram Biomedic venture into COVID-19 molecular diagnostic and vaccine research & development [5 June 2020]

 

Earlier announcement:

OTHERS INCORPORATION OF A NEW SUB-SUBSIDIARY UNDER THE COMPANIES ACT 2016

NEXGRAM HOLDINGS BERHAD

 

Type Announcement
Subject OTHERS
Description
INCORPORATION OF A NEW SUB-SUBSIDIARY UNDER THE COMPANIES ACT 2016

NEXGRAM HOLDINGS BERHAD (660055-H)

INCORPORATION OF A NEW SUB-SUBSIDIARY  

NEXGRAM BIOMEDIC SDN. BHD.  

 

1. INTRODUCTION

Announcement pursuant to Paragraph 9.19(24) of the Ace Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of Nexgram Holdings Berhad (“NEXGRAM” or “the Company”) is pleased to announce that Nexgram had on 2 June 2020 incorporated a sub-subsidiary under the laws of the Companies Act 2016, namely Nexgram Biomedic Sdn. Bhd.  (Company No. 1369237-A)  (“NEXGRAM BIOMEDIC”).

 

2. INFORMATION ON NEXGRAM  SDN. BHD.  

NEXGRAM BIOMEDIC was incorporated as a Company Limited by Shares under the laws of Companies Act 2016 with an issued share capital of RM100,000.00 and in the business of  general, drug and vaccine research and development, manufacturing, sales and distribution of pharmaceutical products and medical instruments.

 

The Directors of NEXGRAM BIOMEDIC are as follows:

 

Directors Nationality
Haji Mazru Bin Mat Yusof. Malaysian
Dato’ Yek Siew Lee Malaysian

 

The Shareholder of NEXGRAM BIOMEDIC and its shareholding in NEXGRAM BIOMEDIC is as follows:

 

Shareholder Number of Shares Shareholding (%)
Nexgram Industries Sdn. Bhd.

(a wholly owned subsidiary of NEXGRAM)

10,000,000 ordinary shares 100%

 

3. RATIONALE OF THE INCORPORATION

The purpose of incorporation of NEXGRAM BIOMEDIC is to expand NEXGRAM business as in carrying various business activities to generate more revenue.

 

4. FINANCIAL EFFECT OF THE INCORPORATION

The incorporation of NEXGRAM BIOMEDIC will not have any material effect on the share capital and substantial shareholders’ shareholdings of NEXGRAM, and is not expected to have any material effect on the earnings per share, net assets per share and gearing of the Group for the financial year ending 31 July 2020.

 

5. INTEREST OF DIRECTORS AND/OR SUBSTANTIAL SHAREHOLDERS  AND/OR PERSONS CONNECTED TO THEM

Save for Haji Mazru Bin Mat Yusof and Dato’ Yek Siew Lee, who are the Directors of NEXGRAM and acting as NEXGRAM’s Representatives in NEXGRAM BIOMEDIC, has declared his interest by virtue of the fact that they are the first director in NEXGRAM BIOMEDIC, none of the Directors and/or substantial shareholders of NEXGRAM and/or persons connected with them have any interest direct or indirect, in the above incorporation.

 

6. STATEMENT BY THE BOARD OF DIRECTORS

The Board of Directors of NEXGRAM is of the opinion that the above incorporation is in the best interest of the Company.

 

This Announcement is dated 5 June 2020.